Market Place
Sourcing Support
Panbela Provides Update & Reports Q3 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
Panbela to Host Q3 2024 Earnings Call on Nov 14, 2024
31 Oct 2024 //
GLOBENEWSWIRE
First Patient Enrolled in STK11 Lung Cancer Phase I at Moffitt
24 Sep 2024 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q2 2024 Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
30 Jul 2024 //
GLOBENEWSWIRE
Panbela`s Phase 3 ASPIRE Trial Gets DSMB Nod to Continue Without Changes
24 Jun 2024 //
GLOBENEWSWIRE
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
10 Jun 2024 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q1 2024 Financial Results
15 May 2024 //
GLOBENEWSWIRE
Panbela Issued US, Canada Patent For Eflornithine-Sulindac Combo
06 May 2024 //
GLOBENEWSWIRE
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
01 May 2024 //
GLOBENEWSWIRE
Eflornithine (DFMO) Abstract Accepted for DDW Oral Presentation
30 Apr 2024 //
GLOBENEWSWIRE
Panbela ASPIRE Interim Analysis Pushed To Q1 2025
22 Apr 2024 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at AACR
18 Apr 2024 //
GLOBENEWSWIRE
Panbela Announces Transfer to OTCQB Market
16 Apr 2024 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference
12 Mar 2024 //
GLOBENEWSWIRE
Panbela Regains Compliance with Nasdaq Listing Standards
15 Feb 2024 //
GLOBENEWSWIRE
Panbela Announces Closing of Approximately $9.0 Million Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at AACR
30 Jan 2024 //
GLOBENEWSWIRE
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
29 Jan 2024 //
PRESS RELEASE
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
25 Jan 2024 //
GLOBENEWSWIRE
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
16 Jan 2024 //
GLOBENEWSWIRE
Panbela Announces Exercise of Warrants and Issuance of New Warrants
21 Dec 2023 //
GLOBENEWSWIRE
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine
18 Dec 2023 //
GLOBENEWSWIRE
Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101
04 Dec 2023 //
GLOBENEWSWIRE
Panbela Announces 2nd Independent Safety Review of the ASPIRE Trial
29 Nov 2023 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q3 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Panbela Therapeutics Announces Exercise of Warrants
03 Nov 2023 //
GLOBENEWSWIRE
Panbela Announces Publication of Preclinical and Clinical Data Titled
02 Nov 2023 //
GLOBENEWSWIRE
Panbela Announces Validation for Claims of a Process for Production of SBP-101
31 Oct 2023 //
GLOBENEWSWIRE
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Publication
25 Oct 2023 //
GLOBENEWSWIRE
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
24 Oct 2023 //
GLOBENEWSWIRE
Panbela Announces Issuance of New Patent in China for the Production of SBP-101
26 Sep 2023 //
GLOBENEWSWIRE
Panbela to Present at the LD Micro Investor Conference
19 Sep 2023 //
GLOBENEWSWIRE
Panbela Announces Issuance of New Patent for the Production of Flynpovi
05 Sep 2023 //
GLOBENEWSWIRE
Panbela Announces Issuance of Patent for Claims of Process for SBP-101
14 Aug 2023 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q2 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
31 Jul 2023 //
GLOBENEWSWIRE
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer
24 Jul 2023 //
GLOBENEWSWIRE
Panbela to Receive Up to $9.5M for DFMO Pediatric Neuroblastoma Program
19 Jul 2023 //
GLOBENEWSWIRE
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
10 Jul 2023 //
GLOBENEWSWIRE
Panbela Announces PACES S0820 Ph III Trial Passes Pre-Planned Futility Analysis
28 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at the Endocrine Society Meeting
26 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces Closing of Approximately $8.5 Million Public Offering
21 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
16 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy
13 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting
01 Jun 2023 //
GLOBENEWSWIRE
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
31 May 2023 //
GLOBENEWSWIRE
Panbela and Moffitt partner to carry out trial of NSCLC therapy
23 May 2023 //
CLINICAL TRIALS ARENA
Panbela Announces Trial with Moffitt Cancer Center for Ph I/II Program in STK11
22 May 2023 //
GLOBENEWSWIRE
Panbela Provides Business Update and Reports Q1 2023 Financial Results
04 May 2023 //
GLOBENEWSWIRE
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Panbela Announces Poster Presentation at American Association Cancer Research
19 Apr 2023 //
GLOBENEWSWIRE
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM
11 Apr 2023 //
GLOBENEWSWIRE
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Meeting
10 Apr 2023 //
GLOBENEWSWIRE
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation
06 Apr 2023 //
GLOBENEWSWIRE
Panbela Announces Agreement with Johns Hopkins University School of Medicine
03 Apr 2023 //
GLOBENEWSWIRE
